These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34260531)

  • 21. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
    Moschini L; Loffi M; Regazzoni V; Di Tano G; Gherbesi E; Danzi GB
    Heart Vessels; 2021 Jan; 36(1):115-120. PubMed ID: 32676695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
    Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
    Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QTc interval prolongation in patients infected with SARS-CoV-2 and treated with antiviral drugs.
    Esmel-Vilomara R; Dolader P; Sabaté-Rotes A; Soriano-Arandes A; Gran F; Rosés-Noguer F
    An Pediatr (Engl Ed); 2022 Mar; 96(3):213-220. PubMed ID: 35193834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
    Carron J; Sharif Z; Hussein H; Kennedy M; McAdam B; Sheahan R
    Ir J Med Sci; 2021 Feb; 190(1):403-409. PubMed ID: 32627127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
    Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
    Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
    Shah RR
    J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
    Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
    J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
    Gasperetti A; Biffi M; Duru F; Schiavone M; Ziacchi M; Mitacchione G; Lavalle C; Saguner A; Lanfranchi A; Casalini G; Tocci M; Fabbricatore D; Salghetti F; Mariani MV; Busana M; Bellia A; Cogliati CB; Viale P; Antinori S; Galli M; Galiè N; Tondo C; Forleo GB
    Europace; 2020 Dec; 22(12):1855-1863. PubMed ID: 32971536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
    Cipriani A; Zorzi A; Ceccato D; Capone F; Parolin M; Donato F; Fioretto P; Pesavento R; Previato L; Maffei P; Saller A; Avogaro A; Sarais C; Gregori D; Iliceto S; Vettor R
    Int J Cardiol; 2020 Oct; 316():280-284. PubMed ID: 32439366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.
    Bakhshaliyev N; Uluganyan M; Enhos A; Karacop E; Ozdemir R
    J Electrocardiol; 2020; 62():59-64. PubMed ID: 32827987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?
    Çelik HG; Keske Ş; Şener Ü; Tekbaş M; Kapmaz M; Şahin ŞT; Özyıldırım A; Aytekin S; Aytekin V; Ergönül Ö
    Int J Infect Dis; 2021 Jan; 102():389-391. PubMed ID: 33130195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study.
    Fteiha B; Karameh H; Kurd R; Ziff-Werman B; Feldman I; Bnaya A; Einav S; Orlev A; Ben-Chetrit E
    Int J Clin Pract; 2021 Mar; 75(3):e13767. PubMed ID: 33063447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
    Mancuso S; Spinelli FR; Agati L; Ciardi MR; Garufi C; Natalucci F; Molteni E; Truglia S; Riccieri V; Priori R; Mastroianni CM; Conti F
    Clin Exp Rheumatol; 2022 May; 40(5):890-896. PubMed ID: 35383554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients.
    Million M; Lagier JC; Hourdain J; Franceschi F; Deharo JC; Parola P; Brouqui P
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241095
    [No Abstract]   [Full Text] [Related]  

  • 36. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
    Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
    Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronavirus disease 2019 (COVID-19) and QTc prolongation.
    Changal K; Paternite D; Mack S; Veria S; Bashir R; Patel M; Soni R; Ali M; Mir T; Sheikh M; Ramanathan PK
    BMC Cardiovasc Disord; 2021 Mar; 21(1):158. PubMed ID: 33784966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
    Çap M; Bilge Ö; Işık F; Burak C; Karagöz A; İnci Ü; Akyüz A; Aslan B; Altıntaş B; Altındağ R; Kaya İ; Adıyaman MŞ; Süleymanoğlu M; Kaya Ş; Baysal E
    J Electrocardiol; 2020; 63():115-119. PubMed ID: 33181454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
    Voisin O; Lorc'h EL; Mahé A; Azria P; Borie MF; Hubert S; Ménage E; Guillerm JC; Mourad JJ
    Mayo Clin Proc; 2020 Aug; 95(8):1696-1700. PubMed ID: 32753141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia.
    Gumilang RA; Siswanto ; Anggraeni VY; Trisnawati I; Budiono E; Hartopo AB
    J Arrhythm; 2021 Oct; 37(5):1184-1195. PubMed ID: 34621417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.